Adaptive Biotechnologies Corporation – NASDAQ:ADPT
Founder-led company
Adaptive Biotechnologies stock price today
$12.38
+6.09
+96.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Adaptive Biotechnologies stock price monthly change
+57.25%
month
Adaptive Biotechnologies stock price quarterly change
+57.25%
quarter
Adaptive Biotechnologies stock price yearly change
+23.09%
year
Adaptive Biotechnologies key metrics
Market Cap | 923.84M |
Enterprise value | 1.18B |
P/E | -5.71 |
EV/Sales | 6.40 |
EV/EBITDA | -6.80 |
Price/Sales | 6.30 |
Price/Book | 2.51 |
PEG ratio | -0.50 |
EPS | -1.49 |
Revenue | 174.50M |
EBITDA | -169.08M |
Income | -215.05M |
Revenue Q/Q | 11.22% |
Revenue Y/Y | -5.33% |
Profit margin | -108.06% |
Oper. margin | -108.03% |
Gross margin | 68.52% |
EBIT margin | -108.03% |
EBITDA margin | -96.89% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAdaptive Biotechnologies stock price history
Adaptive Biotechnologies stock forecast
Adaptive Biotechnologies financial statements
| Jun 2023 | 48.92M | -47.81M | -97.72% |
|---|---|---|---|
| Sep 2023 | 37.91M | -50.3M | -132.65% |
| Dec 2023 | 45.78M | -69.44M | -151.67% |
| Mar 2024 | 41.87M | -47.50M | -113.45% |
| Sep 2025 | 53.49M | -41.76M | -78.08% |
|---|---|---|---|
| Oct 2025 | 51.78M | -39.81M | -76.88% |
| Dec 2025 | 58.59M | -35.26M | -60.17% |
| Mar 2026 | 61.7M | -50.71M | -82.2% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 764540000 | 368.57M | 48.21% |
|---|---|---|---|
| Sep 2023 | 717682000 | 356.04M | 49.61% |
| Dec 2023 | 661134000 | 352.85M | 53.37% |
| Mar 2024 | 620323000 | 345.55M | 55.71% |
| Jun 2023 | -23.55M | 37.32M | 1.46M |
|---|---|---|---|
| Sep 2023 | -46.68M | 26.13M | 17K |
| Dec 2023 | -26.93M | 3.20M | 87K |
| Mar 2024 | -38.35M | 44.50M | 44K |
Adaptive Biotechnologies alternative data
| Sep 2023 | 790 |
|---|---|
| Oct 2023 | 790 |
| Nov 2023 | 790 |
| Dec 2023 | 790 |
| Jan 2024 | 790 |
| Feb 2024 | 790 |
| Mar 2024 | 709 |
| Apr 2024 | 709 |
| May 2024 | 709 |
| Jun 2024 | 709 |
| Jul 2024 | 709 |
Adaptive Biotechnologies other data
86.55%
-7.43%
of ADPT is owned by hedge funds
194
-7
123.21M
-9.95M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 181388 |
| Aug 2024 | 0 | 26922 |
| Nov 2024 | 0 | 248 |
| Patent |
|---|
Application Filling date: 20 Jan 2022 Issue date: 11 Aug 2022 |
Application Filling date: 10 May 2021 Issue date: 28 Apr 2022 |
Grant Filling date: 1 May 2020 Issue date: 15 Feb 2022 |
Application METHODS FOR DIAGNOSING INFECTIOUS DISEASE AND DETERMINING HLA STATUS USING IMMUNE REPERTOIRE SEQUENCING Filling date: 9 Jun 2021 Issue date: 9 Dec 2021 |
Grant Utility: Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization Filling date: 11 May 2018 Issue date: 23 Nov 2021 |
Application Filling date: 16 Apr 2021 Issue date: 7 Oct 2021 |
Grant Utility: Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing Filling date: 24 Nov 2015 Issue date: 20 Jul 2021 |
Grant Utility: Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing Filling date: 24 Feb 2016 Issue date: 29 Jun 2021 |
Grant Filling date: 1 Apr 2016 Issue date: 22 Jun 2021 |
Grant Filling date: 23 Dec 2016 Issue date: 8 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Chad M. Robins M.B.A, M.B.A. (1974) Co-Founder, Chief Executive Officer & Chairman | $1,120,000 |
| Dr. Harlan S. Robins Ph.D. (1973) Co-Founder & Chief Scientific Officer | $747,650 |
| Ms. Julie Rubinstein (1972) Pres | $734,770 |
Mr. Chad M. Cohen CPA (1975) Chief Financial Officer | $625,890 |
Dr. Mark Adams (1967) Chief Operating Officer & Chief Technology Officer | $403,400 |
Adaptive Biotechnologies: Not Quite There Yet, Growth Looks Priced
Adaptive Biotechnologies: Getting Closer To The 'Buy Zone'
Adaptive Biotechnologies: Becoming The Next Big Thing In The Biotech Industry
Adaptive Biotechnologies: Good Buy For Long-Term Investors
iM-Top10 And iM-Top50 Of 40 Large Hedge Funds: Trading Update 4/25/2021
-
What's the price of Adaptive Biotechnologies stock today?
One share of Adaptive Biotechnologies stock can currently be purchased for approximately $12.38.
-
When is Adaptive Biotechnologies's next earnings date?
Unfortunately, Adaptive Biotechnologies's (ADPT) next earnings date is currently unknown.
-
Does Adaptive Biotechnologies pay dividends?
No, Adaptive Biotechnologies does not pay dividends.
-
How much money does Adaptive Biotechnologies make?
Adaptive Biotechnologies has a market capitalization of 923.84M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.11% to 170.28M US dollars.
-
What is Adaptive Biotechnologies's stock symbol?
Adaptive Biotechnologies Corporation is traded on the NASDAQ under the ticker symbol "ADPT".
-
What is Adaptive Biotechnologies's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Adaptive Biotechnologies?
Shares of Adaptive Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Adaptive Biotechnologies's key executives?
Adaptive Biotechnologies's management team includes the following people:
- Mr. Chad M. Robins M.B.A, M.B.A. Co-Founder, Chief Executive Officer & Chairman(age: 51, pay: $1,120,000)
- Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer(age: 52, pay: $747,650)
- Ms. Julie Rubinstein Pres(age: 53, pay: $734,770)
- Mr. Chad M. Cohen CPA Chief Financial Officer(age: 50, pay: $625,890)
- Dr. Mark Adams Chief Operating Officer & Chief Technology Officer(age: 58, pay: $403,400)
-
Is Adaptive Biotechnologies founder-led company?
Yes, Adaptive Biotechnologies is a company led by its founders Mr. Chad M. Robins M.B.A, M.B.A. and Dr. Harlan S. Robins Ph.D..
-
How many employees does Adaptive Biotechnologies have?
As Jul 2024, Adaptive Biotechnologies employs 709 workers.
-
When Adaptive Biotechnologies went public?
Adaptive Biotechnologies Corporation is publicly traded company for more then 6 years since IPO on 27 Jun 2019.
-
What is Adaptive Biotechnologies's official website?
The official website for Adaptive Biotechnologies is adaptivebiotech.com.
-
Where are Adaptive Biotechnologies's headquarters?
Adaptive Biotechnologies is headquartered at 1165 Eastlake Avenue East, Seattle, WA.
-
How can i contact Adaptive Biotechnologies?
Adaptive Biotechnologies's mailing address is 1165 Eastlake Avenue East, Seattle, WA and company can be reached via phone at +20 66 590067.
Adaptive Biotechnologies company profile:
Adaptive Biotechnologies Corporation
adaptivebiotech.comExchange:
NASDAQ
Full time employees:
709
Industry:
Biotechnology
Sector:
Healthcare
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
1165 Eastlake Avenue East
Seattle, WA 98109
Seattle, WA 98109
CIK: 0001478320
ISIN: US00650F1093
CUSIP: 00650F109
